Overview

Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder

Status:
Terminated

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety two oral doses of etoricoxib (60 mg and 90 mg) daily in acute soft tissue rheumatism affecting the shoulder.

Phase:

Phase 3

Details

Lead Sponsor:

Clinica Virgen Milagrosa

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Etoricoxib